A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (NCT06385080)

🧪 Interventions in This Study

• Amivantamab (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)
• Paclitaxel (DRUG)
• Carboplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (56 Sites)

Showing the first 25 of 56 sites.

• University of California at San Diego Moores Cancer Center — La Jolla, California
• University of Colorado Denver Anschultz Medical Campus — Aurora, Colorado
• Yale Cancer Center — New Haven, Connecticut
• The University of Chicago Medical Center (UCMC) — Chicago, Illinois
• University of Maryland School of Medicine — Baltimore, Maryland
• Dana Farber Cancer Institute — Boston, Massachusetts
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
• Karmanos Cancer Institute — Detroit, Michigan
• Washington University School Of Medicine — St Louis, Missouri
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Cleveland Clinic — Cleveland, Ohio
• University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
• University of Virginia — Charlottesville, Virginia
• Virginia Cancer Specialists — Fairfax, Virginia
• Beijing Cancer Hospital of Peking University — Beijing,
• West China School of Medicine/West China Hospital, Sichuan University — Cheng Du Shi,
• Linyi Cancer Hospital — Linyi,
• Fudan Cancer Hospital — Shanghai,
• Shanghai East Hospital — Shanghai,
• Union Hospital Tongji Medical College of Huazhong University of Science and Technology — Wuhan,
• Institut Sainte Catherine — Avignon,
• Centre Oscar Lambret — Lille,
• CHU Nantes — Nantes,
• Institut Curie — Paris,

📞 Contact the Study Coordinator

Phone: (844) 434-4210

Email: Participate-In-This-Study1@its.jnj.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Squamous Cell Carcinoma of Head and Neck

• Pembrolizumab Plus Olaparib in LA-HNSCC — Indianapolis, Indiana
• TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC — Tampa, Florida
• HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer — Dallas, Texas
• MicroRNA Markers in Head and Neck Cancers — Aurora, Colorado
• A Clinical Trial Evaluating TG4050 in Head and Neck Cancer — Jacksonville, Florida

Explore by condition: All Squamous Cell Carcinoma of Head and Neck clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.